Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care ...

Genital herpes infections are very common. There are 42 million new infections each year — that averages out to one new person infected each second. While treatments can help with symptoms, there's no ...

Herpes on the penis looks like clusters of small, fluid-filled blisters. The herpes virus is easily spread through intimate contact during oral, anal, or vaginal sex. Men are half as likely as women ...

Vaccines are one of the most important medical inventions of modern times that have saved and enhanced innumerable lives around the world. Despite the technological advances in vaccine design and ...

Infection with the herpes simplex virus (HSV) is for life. Although HSV-2 is the main cause of genital herpes, HSV-1 – the virus responsible for cold sores – can be transmitted by oral sex, so it, too ...

HealthDay News — A once-promising investigational vaccine against herpes viruses showed only 20% efficacy against herpes genital disease in a large clinical trial designed to mimic the general ...